Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has been given a consensus recommendation of “Buy” by the seventeen ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, fifteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $89.53.
Several research analysts have weighed in on NBIX shares. Piper Jaffray Companies reiterated a “buy” rating and issued a $76.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Citigroup reiterated a “buy” rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Leerink Swann reiterated an “outperform” rating and issued a $83.00 price objective (up previously from $72.00) on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. BMO Capital Markets upped their price objective on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. Finally, Deutsche Bank reiterated a “buy” rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd.
In other news, Director Gary A. Lyons sold 10,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $72.92, for a total transaction of $729,200.00. Following the transaction, the director now owns 272,066 shares in the company, valued at approximately $19,839,052.72. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Darin Lippoldt sold 6,279 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $75.04, for a total transaction of $471,176.16. Following the transaction, the insider now owns 19,436 shares in the company, valued at approximately $1,458,477.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 337,950 shares of company stock worth $26,613,876. 4.80% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. TIAA CREF Investment Management LLC grew its stake in Neurocrine Biosciences by 14.5% in the 4th quarter. TIAA CREF Investment Management LLC now owns 352,116 shares of the company’s stock valued at $27,321,000 after buying an additional 44,642 shares during the last quarter. Teachers Advisors LLC grew its stake in Neurocrine Biosciences by 94.9% in the 4th quarter. Teachers Advisors LLC now owns 193,395 shares of the company’s stock valued at $15,006,000 after buying an additional 94,154 shares during the last quarter. Hanseatic Management Services Inc. acquired a new position in Neurocrine Biosciences in the 4th quarter valued at $965,000. Paloma Partners Management Co grew its stake in Neurocrine Biosciences by 33.4% in the 4th quarter. Paloma Partners Management Co now owns 34,145 shares of the company’s stock valued at $2,649,000 after buying an additional 8,557 shares during the last quarter. Finally, Perceptive Advisors LLC grew its stake in Neurocrine Biosciences by 7.5% in the 4th quarter. Perceptive Advisors LLC now owns 5,151,589 shares of the company’s stock valued at $399,712,000 after buying an additional 360,000 shares during the last quarter.
Neurocrine Biosciences (NASDAQ:NBIX) traded up $1.69 during trading on Friday, reaching $85.38. 1,678,433 shares of the company’s stock traded hands, compared to its average volume of 1,030,000. The firm has a market cap of $7,560.00, a price-to-earnings ratio of -38.46, a PEG ratio of 6.41 and a beta of 0.26. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 1 year low of $39.21 and a 1 year high of $91.82.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.11). The business had revenue of $94.52 million for the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter in the previous year, the company posted ($0.51) EPS. research analysts expect that Neurocrine Biosciences will post -1.48 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Receives Consensus Rating of “Buy” from Analysts” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/14/neurocrine-biosciences-inc-nbix-receives-consensus-rating-of-buy-from-analysts.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.